DIA会员及用户请点击登录

登录

忘记用户 ID? or 忘记密码?

Not a Member?

创建账户并加入。

Bethesda North Marriott Hotel and Conference Center

2018 年 10 月 02 日 7:00 上午 - 2018 年 10 月 03 日 3:00 下午

5701 Marinelli Road, , North Bethesda, MD 20852 , USA

Measuring Impact in Patient-Centered Drug Development Conference

Session 2: Metrics Maturity Model

Session Chair(s)

Linda B Sullivan, MBA

Linda B Sullivan, MBA

Senior Fellow

Tufts Center For the Study of Drug Development, United States

Some organizations have robust metric programs and use metrics to support process improvement programs – others use a small number of metrics primarily for program oversight. In this session, what organizations measure and how they use the results will be described in the context of a five-stage metrics maturity model. The characteristics of each stage will be explored as well as the concept of basic, advanced, and exploratory metrics. Throughout the conference participants will use the framework to keep track of metrics described in conference sessions – determining whether they are examples of basic, advanced, or exploratory metrics and to which stage of the framework they align.

Learning Objective : At the conclusion of this session, participants should be able to:
  • Explain how metric programs evolve through the metric maturity model stages
  • Describe the difference between basic, advanced, and exploratory metrics
  • Apply the metric maturity model to measuring the impact of patient-centered drug development approaches

Speaker(s)

Linda B Sullivan, MBA

Metrics Maturity Model

Linda B Sullivan, MBA

Tufts Center For the Study of Drug Development, United States

Senior Fellow

获得信息并保持参与

不要错失任何机会——请加入我们的邮件列表,了解DIA的观点和事件。